Tuesday, November 13, 2018

Investorideas.com Newswire - #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Appoints Pierre Beaudoin as COO

#Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Appoints Pierre Beaudoin as COO

Vancouver, British Columbia - November 13, 2018 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: SIL.V; NYSE American: SILV) ("SilverCrest" or the "Company") is pleased to announce the appointment of Pierre Beaudoin as Chief Operating Officer for the Company. Pierre will dedicate his full attention to the development of the Las Chispas property, and as such, he will be stepping down from the SilverCrest Board in December.

Mr. Beaudoin is a precious metals mining executive with more than 30 years' experience in diversified mining, mineral processing, design, mine construction and start-up. He recently led the construction, start-up, and operation of the Detour Lake Mine, currently Canada's largest gold operation. Mr. Beaudoin previously led valuation studies for several of Barrick's large assets (Chile, Africa, and USA). Mr. Beaudoin started his career as a Mineral Processing professional and has spent more than 20 years working in processing plants in Canada, Australia, Chile, Peru, and the USA.

N. Eric Fier, CPG, P.Eng, and CEO, remarked, "With our continued success at Las Chispas, we are excited to add the necessary people and skill sets to complement our highly experienced and dedicated team. We welcome Pierre's contribution as we move towards breaking ground on the new decline into the Area 51 zone (Babicanora Vein). Also, Pierre will be supervising preparation of the Preliminary Economic Assessment, targeted for completion in Q1 of 2019. This will allow our exploration team to focus on the ongoing expansion and infill drilling program for an updated resource estimate and resource re-categorization. We are excited to have Pierre join the team as COO to help manage this critical period of development for the Company and we also thank him for his contributions at the board level."

The Company has granted stock options under its Stock Option Plan to Mr. Beaudoin for the purchase of 200,000 common shares at an exercise price of $3.30 per common share for a term of five years expiring November 13, 2023. The stock options vest as to 25% on each of February 13, 2019, May 13, 2019, August 13, 2019 and November 13, 2019, and are subject to necessary regulatory approvals.

ABOUT SILVERCREST METALS INC.

SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico's historic precious metal districts. The Company's current focus is on the high-grade, historic Las Chispas mining district in Sonora, Mexico. SilverCrest is the first company to successfully drill-test the historic Las Chispas Project resulting in numerous discoveries. The Company is led by a proven management team in all aspects of the precious metals mining sector, including taking projects through discovery, finance, on time and on budget construction, and production.

N. Eric Fier, CPG, P.Eng
Chief Executive Officer
SilverCrest Metals Inc.

For Further Information:

SilverCrest Metals Inc.
Contact: Fred Cooper, Investor Relations
Telephone: +1 (604) 694-1730
Fax: +1 (604) 357-1313
Toll Free: 1-866-691-1730 (Canada & USA)
Email: info@silvercrestmetals.com
Website: www.silvercrestmetals.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Visit profile page

Get News Alerts on SilverCrest Metals Inc.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: Investorideas.com is compensated by SilverCrest Metals Inc for annual news publishing effective January 2017.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Friday, November 02, 2018

Investorideas.com - Investor Ideas Adds New CSE-Listed Mining, Tech and Gaming Stocks (CSE: $GENI.C, $NLR.C, $RAD.C, $NTAR.C)

Investor Ideas Adds New CSE-Listed Mining, Tech and Gaming Stocks (CSE: $GENI.C, $NLR.C, $RAD.C, $NTAR.C)

Point Roberts, WA and Delta, BC - November 2, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in mining, tech and gaming.

Investorideas.com is a go- to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members . (https://www.investorideas.com/membership/)

This week's new mining companies are working in Canada, Nevada and Asia.

The latest tech company is involved in software and smartphone applications, while the newest gaming company also crosses into tech territory with its augmented reality (AR) solutions for marketing.

Investor Ideas will soon be exploring the AR & VR (augmented and virtual reality) sectors with the addition of a new section within its tech sector stock list - coming soon!

New Mining Companies:

Genius Metals Inc. (CSE:GENI) is a Canadian mineral exploration company focused on the acquisition, exploration and, if warranted, development of natural resource properties of merit in Canada.

Northern Lights Resources Corp. (CSE:NLR) is a growth oriented company focusing on exploring and developing high quality resource projects globally. The Company currently has two advanced exploration projects. The Medicine Springs Project - Nevada is a previous producer with extensive historical drilling including high grade oxide silver, zinc and lead intercepts and is prospective for high grade oxide and sulphide silver, zinc and lead mineralization. The Del Undur Project is a polymetallic deposit located close to the Russian and Chinese border. The project hosts titanium mineralization.

New Tech Companies:

Radial Research Corp. (CSE:RAD) is a technology company that develops online and download technologies and services, including software, websites and smartphone applications, with its initial focus being a language training smartphone application called "Movie Method".

New Gaming Companies:

NexTech AR Solutions Corp. (CSE:NTAR) Operating and advancing a portfolio of Gaming and All-in-One apps known as the "All-In-One-App Portfolio" using its augmented reality technology and providing other augmented reality enhanced marketing services and solutions including through its ARitize platform and AR learning model.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor one of our podcasts or columns or be a guest call us today!

Contact Investorideas.com

800-665-0411

Thursday, November 01, 2018

Investorideas.com Newswire - CORRECTION: #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Reports Best Drill Hole Intercept to Date, More High-Grades at Las Chispas

#SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Reports Best Drill Hole Intercept to Date, More High-Grades at Las Chispas

This document corrects and replaces the press release that was issued earlier today. The correction is limited to the first bullet point in the sub-headline, where it should read "9.9 Metres Grading 3,212 gpt AgEq", instead of "9 Metres Grading 3,212 gpt AgEq"

9.9 Metres Grading 3,212 gpt AgEq
3.5 Metres Grading 4,570 gpt AgEq
11.1 Metres Grading 879 gpt AgEq

Vancouver, British Columbia - November 1, 2018 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: SIL.V; NYSE American: SILV) ("SilverCrest" or the "Company") is pleased to announce further Phase III drill results for the Las Chispas Property (the "Property") located in Sonora, Mexico. As planned, the first seven (7) in-fill drilling results are from the Babicanora Vein including Area 51 and Babicanora Central zones. Results for the first five (5) holes from Area 51 show higher grades and greater vein widths overall than previously reported for nearby drill results (see details below and attached Figures). The planned in-fill program is designed to upgrade the current inferred resource at Las Chispas by improving the drill density to approximately 25 metre centres for confirmation of continuity, grade and thickness of the vein. Although these in-fill holes are within the high-grade footprint of the updated resource announced on September 19, 2018 titled "SilverCrest Expands Las Chispas Inferred Resource 4.3 Million Tonnes at 3.68 gpt Au and 347 gpt Ag, or 623 gpt AgEq for 87 Million Oz AgEq; Includes 1.6 Million Tonnes at 1,091 gpt AgEq for 56 Million Oz AgEq", they were not yet part of the resource.

N. Eric Fier, CPG, P.Eng, and CEO, remarked, "We continue to de-risk Las Chispas with the startup of closely-spaced in-fill drilling for the Babicanora Vein, including the high-grade Area 51 zone. By announcing our best drill hole intercept to date suggests that significant additional potential could be discovered at Las Chispas. Furthermore, we are intercepting high-grade vein mineralization within 5 to 10 metres of our projected target, which helps to increase our confidence in vein location and continuity. With the addition of these first in-fill holes in the Babicanora Vein, we now have an impressive 119 drill intercepts (variable sample widths from 0.5 to 3.2 metres) grading greater than 1,000 gpt AgEq, 30 intercepts greater than 5,000 gpt AgEq and 15 intercepts greater than 10,000 gpt AgEq with our highest single grade being 36,764 gpt AgEq over 0.5 metres from a total of 351 core holes (94,735 metres) drilled to date at Las Chispas. SilverCrest will continue with both its in-fill drilling focused on de-risking our current resources and expansion drilling focused on new discoveries as we systematically work on completing the next updated resource and our Preliminary Economic Assessment ("PEA") in Q1, 2019."

The most significant result for this release is our best intercept (grade x thickness) since commencement of the exploration program in February 2016. Hole BA18-96 intersected 9.9 metres (true width) grading 14.4 gpt Au and 2,132.4 gpt Ag, or 3,212 gpt AgEq. Also noteworthy are holes BA18-94 at 3.5 metres grading 33.06 gpt Au and 2,092.1 gpt Ag, or 4,570 gpt AgEq and BA18-95 at 11.1 metres grading 3.99 gpt Au and 580.2 gpt Ag, or 879 gpt AgEq. The following table summarizes the most significant drill intercepts for this news release (uncut, undiluted).

Babicanora Vein In-Fill Drill Intercepts:

Note: all numbers are rounded.
* AgEq based on 75 (Ag):1 (Au) calculated using long-term silver and gold prices of US$18.50 per ounce silver and US$1,225 per ounce gold, with average metallurgical recoveries of 86.6% silver and 98.9% gold.
**UB signifies an underground core hole. BA is a surface core hole.

All assays were completed by ALS Chemex in Hermosillo, Mexico, and North Vancouver, BC, Canada.

Holes BA18-93 to 97 contain variable amounts of coarse argentite, native silver, electrum and free gold (see attached Figures).

A comparison of the weighted average grade (uncut, undiluted) and true widths of the previous drill hole results in the "Area of Influence" (see attached Figures) versus the combined previous and new drill hole results shows an increase of 35% in width and 13% in AgEq grade based on the following:

Weighted average for previous drill results (10 holes): 2.9 metres grading 9.06 gpt Au and 980.5 gpt Ag, or 1,661 gpt AgEq.
Weighted average for new drill results (5 holes, table): 6.0 metres grading 11.41 gpt Au and 1,368.9 gpt Ag, or 2,224 gpt AgEq.
Weighted average for previous and new drill results (15 holes): 3.9 metres grading 10.33 gpt Au and 1,189.8 gpt Ag, or 1,964 gpt AgEq.

This general comparison is based on the first five in-fill holes to be reported in the Area 51 zone. Further in-fill drilling is underway, and initial results may not be indicative of additional future results.

The Company continues its Phase III exploration program with eight (8) drills operating on site, seven on surface and one underground. Drills are focused on expanding mineralization for inclusion in the next updated resource anticipated in Q1, 2019, and in-fill drilling (estimated 25 metre spacing) to reclassify Inferred Resources to Measured and Indicated. An additional 15,000 to 20,000 metres of drilling are planned for inclusion in the next updated resource. Other ongoing site work includes PEA work, final design work for the Area 51 decline, an extensive metallurgical test program, drilling large diameter wells for site water, and permitting for various additional work.

The Qualified Person under National Instrument 43-101 Standards of Disclosure for Mineral Projects for this news release is N. Eric Fier, CPG, P.Eng, and CEO for SilverCrest, who has reviewed and approved its contents.

Figure 1: Long Section (Inclined) of Babicanora Vein Las Chispas Property, Looking Southwest

Figure 2: Long Section (Inclined) of Babicanora Vein Area 51, Looking Southwest

Figure 3: Las Chispas District with Babicanora Plan Map, October 2018

ABOUT SILVERCREST METALS INC.

SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions, and targeting production in Mexico's historic precious metal districts. The Company's current focus is on the high-grade, historic Las Chispas mining district in Sonora, Mexico. SilverCrest is the first company to successfully drill-test the historic Las Chispas Project resulting in numerous discoveries. The Company is led by a proven management team in all aspects of the precious metal mining sector, including taking projects through discovery, finance, on time and on budget construction, and production.

FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking statements" within the meaning of Canadian securities legislation. These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company's exploration, rehabilitation and drilling programs of the Las Chispas Property, including drilling test water wells, permitting for various work, and optimizing and updating the Company's resource model; information with respect to high grade areas and size of veins projected from underground sampling results and drilling results; and the accessibility of future mining at the Las Chispas Property. Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: the conditions in general economic and financial markets; availability of skilled labour; timing and amount of expenditures related to rehabilitation and drilling programs; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors including: the timing and content of work programs; results of exploration activities; the interpretation of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

N. Eric Fier, CPG, P.Eng
Chief Executive Officer
SilverCrest Metals Inc.

For Further Information:

Contact: Fred Cooper, Investor Relations
Telephone: +1 (604) 694-1730
Fax: +1 (604) 357-1313
Toll Free: 1-866-691-1730 (Canada & USA)
Email: info@silvercrestmetals.com
Website: www.silvercrestmetals.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Visit profile page

Get News Alerts on SilverCrest Metals Inc.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Wednesday, October 31, 2018

Investorideas.com Newswire - #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Announces Changes to Board of Directors and Provides Project Update

#Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Announces Changes to Board of Directors and Provides Project Update

Vancouver, British Columbia - October 31, 2018 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: SIL.V; NYSE American: SILV) ("SilverCrest" or the "Company") is pleased to announce the appointment of Hannes Portmann to the Board of Directors replacing George Sanders, who is retiring from the Board. SilverCrest is also pleased to provide a brief update of ongoing activities at the Las Chispas project.

Mr. Portmann is a mining executive with significant management and capital markets experience. Through May 2018, he spent 10 years with New Gold Inc., ultimately serving as President and Chief Executive Officer of the intermediate gold producer. Previously, Mr. Portmann served as Executive Vice President, Business Development with primary responsibilities including corporate development, investor relations, human resources, and exploration. Prior to New Gold, Mr. Portmann was a member of the Merrill Lynch investment banking mining group and the assurance and advisory practices of PricewaterhouseCoopers LLP. Mr. Portmann holds a Bachelor of Science in Mining Engineering from Queen's University and a Masters of Management and Professional Accounting from the Rotman School of Management, University of Toronto.

N. Eric Fier, CPG, P.Eng, and CEO, remarked, "We would like to thank George Sanders for his leadership and guidance during the Company's expansion of the Las Chispas project. His advice and strategic expertise made a significant contribution to SilverCrest's success as we navigated a challenging mining investment climate. We are happy to welcome Hannes Portmann to the Board of Directors. Hannes brings significant strategic planning, finance and capital markets experience to the Board, which should prove invaluable as we look to build shareholder value by advancing the Las Chispas project and the Company."

On October 2, 2018, SilverCrest retained the services of Tetra Tech Inc. of Vancouver, BC to complete a Preliminary Economic Assessment ("PEA") for the Las Chispas project. The PEA will consider the conceptual economics of developing a 1,000 to 1,500 tonne per day underground mining operation with a counter-current decantation facility (CCD) and Merrill Crowe recovery circuit similar to the nearby Santa Elena and Mercedes mines. The PEA is expected to be completed in Q1, 2019. As part of the PEA, the Company is completing expansion and in-fill drilling and detailed metallurgy testwork at Las Chispas. Given the high-grade nature of Las Chispas, the Company is evaluating cyanidation with a possible add-on flotation circuit followed by intense leaching for greater than 1,000 grams per tonne silver equivalent material. This test work will help determine the potential for higher silver recoveries using both cyanidation and flotation methods. Initial metallurgical testwork completed in November 2017 showed average recoveries of 86.6% for silver and 98% for gold using standard cyanidation only.

SilverCrest is proceeding with the construction of an exploration decline to access the Babicanora Vein, Area 51 zone. The Company is finalizing its selection of contractors to construct this decline, estimated to be 500 metres long, 4.5 metres wide by 4.0 metres in height. The work will also include drifting 600 to 800 metres along the strike of vein mineralization to collect information on vein grade and width continuity, reconciliation with the resource model, geotechnical parameters, mineability, and bulk sampling for additional metallurgical testwork. During the construction of the exploration decline, the Company will set up drill stations to further in-fill drill the Area 51 zone and test for extensions at depth. The Company expects to be drifting in high-grade mineralization and stockpiling of this material in the second half of 2019. As previously stated in the Company's May 2018 prospectus offering, the total estimated cost of the decline and associated exploration work is approximately US$3 million, which will be funded by the Company's current cash position of approximately C$12.3 million.

ABOUT SILVERCREST METALS INC.

FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking statements" within the meaning of Canadian securities legislation. These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company's exploration, rehabilitation and drilling programs of the Las Chispas Property, including expansion and in-fill drilling, detailed metallurgy testwork, completing a PEA, constructing an exploration decline, permitting for various work, and optimizing and updating the Company's resource model; information with respect to high grade areas and size of veins projected from underground sampling results and drilling results; accessibility of future mining at the Las Chispas Property and status of mineral titles. Such forward‑looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: the conditions in general economic and financial markets; availability of skilled labour; timing and amount of expenditures related to rehabilitation and drilling programs; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors including: the timing and content of work programs; results of exploration activities; the interpretation of drilling results and other geological data; receipt, maintenance and security of permits and status of mineral property titles; environmental and other regulatory risks; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

N. Eric Fier, CPG, P.Eng
Chief Executive Officer
SilverCrest Metals Inc.

For Further Information:

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Visit profile page

Get News Alerts on SilverCrest Metals Inc.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Friday, October 26, 2018

Investorideas.com - Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

CSE-Listed Stocks in #Mining, #Energy and #Nanotech (CSE: $CRES, $DLRY, $KAL, $SENS, $SONA)

Point Roberts, WA and Delta, BC - October 26, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in biotech, mining, energy and nanotech.

New biotech companies are all recent Nasdaq IPO's and include biotech, oncology, biopharma and life sciences companies providing treatments for cancer, autoimmune and ophthalmic diseases.

The latest mining companies are all CSE-Listed and operate in Canada, while the newest energy company (also CSE-Listed), is a leading solutions provider to various sectors including the oil and gas industry.

Finally, the newest nanotech company Sona Nanotech Inc. (CSE: SONA), also crosses over into the biotech (life sciences) sector with their rod-shaped gold nanoparticles which are used in multiplex diagnostic testing platforms.

New Biotech Companies:

ALLOGENE THERAPEUTICS, INC. (NasdaqGS: ALLO) with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer.

EQUILLIUM, INC (NasdaqGM: EQ) is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium's initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.

GUARDANT HEALTH, INC. (NasdaqGS: GH) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.

KODIAK SCIENCES INC. (NasdaqGM: KOD) is a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas. Our Antibody Biopolymer Conjugate, or ABC Platform™, merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a potential best in class molecule for age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform™ to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA.

PRINCIPIA BIOPHARMA INC. (NasdaqGS:PRNB) is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia's proprietary Tailored Covalency® platform enables Principia to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics, yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 2 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with ITP, a rare hematological disease. PRN2246, a covalent BTK inhibitor which crosses the blood-brain barrier, has completed a Phase 1 clinical trial in healthy volunteers, and has been partnered with Sanofi for development in multiple sclerosis and, potentially, for other diseases of the CNS. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor (FGFR), is being evaluated in a Phase 1 trial in patients with solid tumors.

Y-mAbs THERAPEUTICS, INC. (NasdaqGS: YMAB) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates-naxitamab and omburtamab-which target tumors that express GD2 and B7-H3, respectively.

New Mining Companies:

Crest Resources Inc. (CSE: CRES) is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Red Metal Ridge Property. The Red Metal Ridge Property is comprised of six contiguous mineral titles covering an area of 1381.50 hectares, located 74 kilometres northwest of the town of Campbell River and 12 kilometres southwest of the town of Sayward on Vancouver Island, British Columbia, Canada.

Delrey Metals Corp. (CSE:DLRY) is an exploration stage mineral resources company whose principal business activities include acquiring, exploring and evaluating strategic energy mineral properties

Kal Minerals Corp. (CSE: KAL) is a Canadian junior mineral exploration company with a specific focus on properties in the New Westminster Mining Division of British Columbia, Canada. The Company's sole property, the Jack White Property, is comprised of four mineral tenures covering approximately 2,202 hectares approximately 13km northeast of Boston Bar, British Columbia.

New Energy Companies:

Sensor Technologies Inc. (CSE:SENS) - formerly Mooncor Oil and Gas Corp - is a leading solutions provider to various sectors including the oil and gas industry. With non-intrusive technologies including fiber-optic sensors and electric field mapping EFM systems. Sensor Technologies Corp is able to accurately measure changes that could negatively impact our client's operations. SENS F.O. sensors are a non-invasive tool for monitoring pipeline defects in real time. consist of non-intrusive sensors, monitor & software. SENS's EFM monitoring of isolated pit formation & growth using a non-permanent modular design based on electrical resistance measurements, monitoring locations may be placed hundreds of feet away from the sensors. Software operates in continuous or scheduled reporting modes. SENS's latest tech, is its leak detection system, for use in application such as Pipe sections at remote facilities Monitoring of Military, Scientific installations for corrosive liquids in harsh environments , in tank farms, pipe sections, Water leak detection in data centers & buildings.

New Nanotech Companies:

Sona Nanotech Inc. (CSE: SONA) is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor one of our podcasts or columns or be a guest call us today!

Contact Investorideas.com

800-665-0411

Friday, October 12, 2018

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Point Roberts, WA and Delta, BC - September 21, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech and mining.

The newest companies in biotech are all Nasdaq IPO listings from within the past few weeks and include pharmaceutical, medical device and biopharma companies looking to treat a variety of diseases and unmet medical conditions/needs.

The latest mining company is a recent CSE listing that is exploring and developing properties in Quebec and BC, Canada.

New Biotech Companies

ADIAL PHARMACEUTICALS, INC. (NasdaqCM: ADIL) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

ALLAKOS INC. (NasdaqGS:ALLK) is a clinical stage company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, AK002, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed two Phase 1 trials, one in healthy volunteers and a single ascending dose trial in patients with indolent systemic mastocytosis. AK002 demonstrated pharmacodynamic activity in both trials and in the trial involving patients with indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a Phase 2 trial for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis. In addition, Allakos is conducting multiple-dose trials with AK002 in chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

AQUESTIVE THERAPEUTICS, INC. (NasdaqGM: AQST) is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

CONSTELLATION PHARMACEUTICALS INC (NasdaqGS:CNST) is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. With a decade of experience in the field, the Company has a deep understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the Company's two lead clinical programs, the EZH2 inhibitor CPI-1205 for metastatic castration-resistant prostate cancer and solid tumors and the BET inhibitor CPI-0610 for myelofibrosis, and to explore other novel targets for which cancer epigenetics may enhance outcomes over currently available treatment options.

CRINETICS PHARMACEUTICALS, INC. (NasdaqGS:CRNX) is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development.

ESTABLISHMENT LABS HOLDINGS INC. (NasdaqCM:ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 60 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes the Divina® 3D Simulation System, Puregraft and MotivaImage® Centers.

LIQUIDIA TECHNOLOGIES INC (NasdaqCM: LQDA) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia's lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology.

PROVENTION BIO, INC (NasdaqCM:PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Our diverse portfolio was assembled with product candidates that have undergone clinical testing but may have been underdeveloped or deprioritized assets at other companies. Provention's mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, lupus, and certain life-threating viral diseases.

REPLIMUNE GROUP, INC. (NasdaqGS:REPL) headquartered in Woburn, MA, was founded in 2015 to develop the next generation of "oncolytic immunotherapies" for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action

RUBIUS THERAPEUTICS, INC. (NasdaqGS:RUBY) is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction

VACCINEX, INC. (NasdqGM: VCNX) is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

New Mining Companies

Zenith Exploration Inc. (CSE:ZX) is a resource exploration issuer that acquires and explores mineral properties. Zenith's principal property is in Quebec and its secondary property is in BC. The Company intends to explore and develop these properties.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

To sponsor one of our podcasts or columns or be a guest call us today!

Contact Investorideas.com

https://www.investorideas.com/About/Contact.asp

800-665-0411

About Investorideas.com

About Investorideas.com - Big Investing Ideas Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Disclaimer

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: For disclosure purposes SinglePoint Inc. (OTCQB: SING) is a paid news, PR and social media client on Investorideas.com

https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Disclaimer/ disclosure

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Investorideas.com Social Media Disclaimer :

Investorideas.com supports the use of social media however content posted through these channels (Facebook, Twitter, LinkedIn, etc) is not to be taken as an endorsement of the information as we are not always able to ensure its original accuracy. Information provided on social media sites is not deemed to be a binding representation, agreement or endorsement on the part of the company. Please do your due diligence and always check facts in online communication channels. If any questions arise in this regard, feel free to contact us .

Gold Stocks and Mining Stocks News, Investing and Trading Ideas

Tuesday, November 13, 2018

Investorideas.com Newswire - #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Appoints Pierre Beaudoin as COO

#Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Appoints Pierre Beaudoin as COO

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Friday, November 02, 2018

Investorideas.com - Investor Ideas Adds New CSE-Listed Mining, Tech and Gaming Stocks (CSE: $GENI.C, $NLR.C, $RAD.C, $NTAR.C)

Investor Ideas Adds New CSE-Listed Mining, Tech and Gaming Stocks (CSE: $GENI.C, $NLR.C, $RAD.C, $NTAR.C)

Thursday, November 01, 2018

Investorideas.com Newswire - CORRECTION: #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Reports Best Drill Hole Intercept to Date, More High-Grades at Las Chispas

#SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Reports Best Drill Hole Intercept to Date, More High-Grades at Las Chispas

This document corrects and replaces the press release that was issued earlier today. The correction is limited to the first bullet point in the sub-headline, where it should read "9.9 Metres Grading 3,212 gpt AgEq", instead of "9 Metres Grading 3,212 gpt AgEq"

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Wednesday, October 31, 2018

Investorideas.com Newswire - #Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Announces Changes to Board of Directors and Provides Project Update

#Mining Stock News: #SilverCrest (TSXV: $SIL.V; NYSE: $SILV) Announces Changes to Board of Directors and Provides Project Update

SilverCrest Metals Inc. (TSXV: SIL.V; NYSE: SILV) is a featured company on Investorideas.com

Friday, October 26, 2018

Investorideas.com - Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks

CSE-Listed Stocks in #Mining, #Energy and #Nanotech (CSE: $CRES, $DLRY, $KAL, $SENS, $SONA)

Friday, October 12, 2018

Investorideas.com - Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Investor Ideas adds Nasdaq #Biotech #IPOs and CSE #Mining IPO Stocks to Directories (NASDAQ: $ADIL), (NASDAQ: $ALLK) (NASDAQ: $AQST), (CSE: $ZX.C)

Mining stocks news alerts

Blog Archive

Links

Disclaimer/ disclosure